WO2011018588A2 - OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE - Google Patents
OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE Download PDFInfo
- Publication number
- WO2011018588A2 WO2011018588A2 PCT/FR2010/051703 FR2010051703W WO2011018588A2 WO 2011018588 A2 WO2011018588 A2 WO 2011018588A2 FR 2010051703 W FR2010051703 W FR 2010051703W WO 2011018588 A2 WO2011018588 A2 WO 2011018588A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sodium
- deoxy
- idopyranosyluronate
- sulfonato
- glucopyranosyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract description 171
- 230000001225 therapeutic effect Effects 0.000 title abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 18
- 125000003118 aryl group Chemical group 0.000 claims abstract description 8
- 239000011734 sodium Substances 0.000 claims description 782
- 229910052708 sodium Inorganic materials 0.000 claims description 720
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 305
- 150000001875 compounds Chemical class 0.000 claims description 269
- -1 1-oxobutyl Chemical group 0.000 claims description 247
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 197
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 230000004083 survival effect Effects 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 230000008439 repair process Effects 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 108091008794 FGF receptors Proteins 0.000 claims description 14
- 150000002016 disaccharides Chemical class 0.000 claims description 14
- 230000000250 revascularization Effects 0.000 claims description 12
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 10
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 230000007170 pathology Effects 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 230000004224 protection Effects 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 8
- 210000000496 pancreas Anatomy 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 210000000845 cartilage Anatomy 0.000 claims description 6
- 210000003780 hair follicle Anatomy 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 210000003098 myoblast Anatomy 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000033386 Buerger disease Diseases 0.000 claims description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 4
- 238000002399 angioplasty Methods 0.000 claims description 4
- 206010003230 arteritis Diseases 0.000 claims description 4
- 125000005524 levulinyl group Chemical group 0.000 claims description 4
- 210000003141 lower extremity Anatomy 0.000 claims description 4
- 230000009756 muscle regeneration Effects 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 231100000216 vascular lesion Toxicity 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 201000007737 Retinal degeneration Diseases 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 201000011461 pre-eclampsia Diseases 0.000 claims description 3
- 230000004258 retinal degeneration Effects 0.000 claims description 3
- 208000028389 Nerve injury Diseases 0.000 claims description 2
- 230000003779 hair growth Effects 0.000 claims description 2
- 230000008764 nerve damage Effects 0.000 claims description 2
- 230000026341 positive regulation of angiogenesis Effects 0.000 claims description 2
- RHMWVNFRRRZAAQ-DVKNGEFBSA-N (2s,3r,4s,5s,6r)-2-aminooxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound NO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RHMWVNFRRRZAAQ-DVKNGEFBSA-N 0.000 claims 1
- 125000000600 disaccharide group Chemical group 0.000 abstract 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 315
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 228
- 239000000243 solution Substances 0.000 description 182
- 229910052744 lithium Inorganic materials 0.000 description 142
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 123
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 121
- 239000000203 mixture Substances 0.000 description 106
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 104
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 102
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 93
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 90
- 239000000741 silica gel Substances 0.000 description 85
- 229910002027 silica gel Inorganic materials 0.000 description 85
- 239000000047 product Substances 0.000 description 82
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 81
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 81
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
- 238000003756 stirring Methods 0.000 description 72
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 68
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 60
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 60
- 235000017557 sodium bicarbonate Nutrition 0.000 description 60
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 58
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 57
- 238000000034 method Methods 0.000 description 55
- 239000011541 reaction mixture Substances 0.000 description 54
- 230000015572 biosynthetic process Effects 0.000 description 52
- 238000003786 synthesis reaction Methods 0.000 description 51
- 239000012429 reaction media Substances 0.000 description 46
- 239000003480 eluent Substances 0.000 description 45
- 239000007864 aqueous solution Substances 0.000 description 41
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 40
- 238000003760 magnetic stirring Methods 0.000 description 40
- 239000011780 sodium chloride Substances 0.000 description 40
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 39
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 39
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 39
- 229920005654 Sephadex Polymers 0.000 description 38
- 239000012507 Sephadex™ Substances 0.000 description 38
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 35
- 229910052786 argon Inorganic materials 0.000 description 34
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- 238000001914 filtration Methods 0.000 description 30
- 239000000126 substance Substances 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000002808 molecular sieve Substances 0.000 description 28
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 230000033115 angiogenesis Effects 0.000 description 24
- XYKIUTSFQGXHOW-UHFFFAOYSA-N propan-2-one;toluene Chemical compound CC(C)=O.CC1=CC=CC=C1 XYKIUTSFQGXHOW-UHFFFAOYSA-N 0.000 description 24
- 229920006395 saturated elastomer Polymers 0.000 description 24
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 23
- 239000000937 glycosyl acceptor Substances 0.000 description 23
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 22
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- MSQDVGOEBXMPRF-UHFFFAOYSA-N cyclohexane;propan-2-one Chemical compound CC(C)=O.C1CCCCC1 MSQDVGOEBXMPRF-UHFFFAOYSA-N 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 19
- 238000006073 displacement reaction Methods 0.000 description 19
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 16
- 229940126864 fibroblast growth factor Drugs 0.000 description 16
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 16
- 0 CC(OCC([C@](C([C@@](*)N)OCc1ccccc1)O[C@@](C(C([C@](*)CC(OC)=O)OCc1ccccc1)OC(C)=O)O)OC=*)=O Chemical compound CC(OCC([C@](C([C@@](*)N)OCc1ccccc1)O[C@@](C(C([C@](*)CC(OC)=O)OCc1ccccc1)OC(C)=O)O)OC=*)=O 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 238000001035 drying Methods 0.000 description 15
- 238000001704 evaporation Methods 0.000 description 15
- 230000008020 evaporation Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 14
- 229920001542 oligosaccharide Polymers 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 150000002482 oligosaccharides Chemical class 0.000 description 13
- YFHNDHXQDJQEEE-UHFFFAOYSA-N acetic acid;hydrazine Chemical compound NN.CC(O)=O YFHNDHXQDJQEEE-UHFFFAOYSA-N 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 10
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 10
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical group [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 8
- 229910052763 palladium Inorganic materials 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- WACQKHWOTAEEFS-UHFFFAOYSA-N cyclohexane;ethyl acetate Chemical compound CCOC(C)=O.C1CCCCC1 WACQKHWOTAEEFS-UHFFFAOYSA-N 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 6
- KMRMATGZQDHMSQ-RKQHYHRCSA-N C(=O)=N[C@]1(OOCC2=CC=CC=C2)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO Chemical compound C(=O)=N[C@]1(OOCC2=CC=CC=C2)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO KMRMATGZQDHMSQ-RKQHYHRCSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 6
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 5
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940044601 receptor agonist Drugs 0.000 description 5
- 239000000018 receptor agonist Substances 0.000 description 5
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KMRMATGZQDHMSQ-RGDJUOJXSA-N (2S,3R,4S,5S,6R)-2-benzylperoxy-6-(hydroxymethyl)-2-isocyanatooxane-3,4,5-triol Chemical compound C(=O)=N[C@@]1(OOCC2=CC=CC=C2)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO KMRMATGZQDHMSQ-RGDJUOJXSA-N 0.000 description 4
- OFDPEKFHZNICPM-WYRLRVFGSA-N (2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl.OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O OFDPEKFHZNICPM-WYRLRVFGSA-N 0.000 description 4
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 4
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000027746 artery morphogenesis Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000348 glycosyl donor Substances 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- 108091008695 photoreceptors Proteins 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010061876 Obstruction Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- BNNQNALSLWKHIV-UHFFFAOYSA-N butanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound CCCC(O)=O.ON1C(=O)CCC1=O BNNQNALSLWKHIV-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 3
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 3
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000004702 methyl esters Chemical group 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N (2-methylphenyl)methanol Chemical compound CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 2
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 2
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 2
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 2
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 2
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 2
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 2
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 2
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 2
- 108091016585 CD44 antigen Proteins 0.000 description 2
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 108090000054 Syndecan-2 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- NBVZMBLJRHUOJR-UHFFFAOYSA-N [amino-[4-[6-[4-[amino(azaniumylidene)methyl]phenoxy]hexoxy]phenyl]methylidene]azanium;2-hydroxyethanesulfonate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 NBVZMBLJRHUOJR-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 229940126179 compound 72 Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- SMBQBQBNOXIFSF-UHFFFAOYSA-N dilithium Chemical compound [Li][Li] SMBQBQBNOXIFSF-UHFFFAOYSA-N 0.000 description 2
- 239000000386 donor Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical group 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
- 239000001120 potassium sulphate Substances 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- AAZYNPCMLRQUHI-UHFFFAOYSA-N propan-2-one;2-propan-2-yloxypropane Chemical compound CC(C)=O.CC(C)OC(C)C AAZYNPCMLRQUHI-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DVFXLNFDWATPMW-IWOKLKJTSA-N tert-butyldiphenylsilyl Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DVFXLNFDWATPMW-IWOKLKJTSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- JSMJOZYWNAPUMO-SYLRKERUSA-N (1r,2s,3r,4r,5r)-4-azido-3-phenylmethoxy-6,8-dioxabicyclo[3.2.1]octan-2-ol Chemical compound O([C@@H]1[C@@H](N=[N+]=[N-])[C@]2([H])OC[C@@](O2)([C@H]1O)[H])CC1=CC=CC=C1 JSMJOZYWNAPUMO-SYLRKERUSA-N 0.000 description 1
- KVIRZVGRJFHUAS-SYLRKERUSA-N (2R,3R,4R,5S,6R)-3-azido-6-(hydroxymethyl)-4-phenylmethoxyoxane-2,5-diol Chemical compound N(=[N+]=[N-])[C@H]1[C@H](O)O[C@@H]([C@H]([C@@H]1OCC1=CC=CC=C1)O)CO KVIRZVGRJFHUAS-SYLRKERUSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 101710194912 18 kDa protein Proteins 0.000 description 1
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- LASHFHLFDRTERB-UHFFFAOYSA-N 2-propylpentan-1-ol Chemical compound CCCC(CO)CCC LASHFHLFDRTERB-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- DPZMVZIQRMVBBW-UHFFFAOYSA-N 5-Phenyl-1-pentanol Chemical compound OCCCCCC1=CC=CC=C1 DPZMVZIQRMVBBW-UHFFFAOYSA-N 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 206010061762 Chondropathy Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241001643084 Cyrtanthus elatus virus A Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710124086 Envelope protein UL45 Proteins 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101001060265 Homo sapiens Fibroblast growth factor 6 Proteins 0.000 description 1
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000030768 Optic nerve injury Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 229930182475 S-glycoside Natural products 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- PNPBGYBHLCEVMK-UHFFFAOYSA-N benzylidene(dichloro)ruthenium;tricyclohexylphosphanium Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-N 0.000 description 1
- FCDPQMAOJARMTG-UHFFFAOYSA-M benzylidene-[1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichlororuthenium;tricyclohexylphosphanium Chemical compound C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.CC1=CC(C)=CC(C)=C1N(CCN1C=2C(=CC(C)=CC=2C)C)C1=[Ru](Cl)(Cl)=CC1=CC=CC=C1 FCDPQMAOJARMTG-UHFFFAOYSA-M 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-M cyclopentanecarboxylate Chemical compound [O-]C(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-M 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000006832 extrinsic signaling Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000011984 grubbs catalyst Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- XNIUOUYFSNUYAQ-UHFFFAOYSA-N hexanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound CCCCCC(O)=O.ON1C(=O)CCC1=O XNIUOUYFSNUYAQ-UHFFFAOYSA-N 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006831 intrinsic signaling Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- YYHPEVZFVMVUNJ-UHFFFAOYSA-N n,n-diethylethanamine;sulfur trioxide Chemical compound O=S(=O)=O.CCN(CC)CC YYHPEVZFVMVUNJ-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004263 retinal angiogenesis Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 230000004276 retinal vascularization Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000011986 second-generation catalyst Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 210000001738 temporomandibular joint Anatomy 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003569 thioglycosides Chemical class 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009441 vascular protection Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 150000008501 α-D-glucopyranosides Chemical class 0.000 description 1
- 150000008505 β-D-glucopyranosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
Definitions
- the present invention relates to N-acylated agonist octasaccharides of the FGFs / FGFRs system, to their preparation and to their therapeutic application.
- Angiogenesis is a process of generating new capillaries. When obstruction of a blood vessel, angiogenesis, associated with arteriogenesis (dilation of capillaries), improves revascularization of the obstructed area. It has been shown in vitro and in vivo that several growth factors, such as Fibroblast Growth Factors (FGFs), stimulate the process of neovascularization.
- FGFs Fibroblast Growth Factors
- FGF2 (or basic FGF) is an 18 kDa protein. FGF2 induces at the endothelial cells in culture their proliferation, their migration and the production of proteases. In vivo, FGF2 promotes neovascularization phenomena. FGF2 interacts with endothelial cells via two classes of receptors, high affinity receptors with tyrosine kinase activity (FGFRs) and low affinity heparan sulfate proteoglycan (HSPG) receptors.
- FGFRs tyrosine kinase activity
- HSPG heparan sulfate proteoglycan
- tyrosine kinase cell surface receptors associate as a dimer with a complex of two ligand molecules and a heparan sulfate molecule. The formation of this complex triggers a cascade of intracellular signals leading to the activation of proliferation and cell migration, two key processes involved in angiogenesis.
- FGF2 and its receptors represent highly relevant targets for therapies aimed at activating or inhibiting angiogenesis processes.
- Synthetic oligosaccharides have also been the subject of interaction studies with FGF receptors (C. Tabeur et al., Bioorg et al., Chem., 1999, 7, 2003-2012, C. Noti et al. J. Chem., 2006, 12, 8664-8686).
- novel synthetic oligosaccharide compounds capable of facilitating the formation of the FGF / FGFRs complex and thus promoting the survival of endothelial cells in vitro and increasing the formation of neovessels in vitro and in vivo.
- the present invention relates to novel octasaccharide compounds corresponding to formula (I):
- the wavy line denotes a bond situated either below or above the plane of the pyranosic ring of the glucosamine unit
- R 1 represents an O-alkyl group, in which said alkyl group comprises from 1 to 16 carbon atoms and is optionally substituted by one or more (for example 1 or 2) groups, identical or different, chosen from aryl and cycloalkyl groups; ,
- R 2 represents either a 3 " OSO group or a hydroxyl group
- R 3 represents an alkyl, cycloalkyl or alkyl-cycloalkyl group
- R 4 represents a disaccharide of formula (II):
- R 3 is as defined above
- R 5 represents either a 3 " OSO group or a hydroxyl group
- R 3 is as defined above
- R 7 represents either a 3 " OSO group or a hydroxyl group
- R 3 represents a disaccharide of formula (IV):
- R 3 is as defined above
- R 9 represents either a 3 " OSO group or a hydroxyl group.
- alkyl group a saturated linear or branched aliphatic group. Unless otherwise indicated in the text, such an alkyl group advantageously comprises between 1 and 6 carbon atoms.
- alkyl group advantageously comprises between 1 and 6 carbon atoms.
- cycloalkyl group a cyclic alkyl group comprising from 3 to 6 carbon atoms, for example a cyclopentyl or cyclohexyl group;
- alkyl-cycloalkyl group an alkyl group itself substituted with a cycloalkyl group, said alkyl and cycloalkyl groups being as defined above;
- aryl group a cyclic aromatic group comprising between 5 and 10 carbon atoms, such as a phenyl group. Such an aryl group is optionally substituted with one or more groups such as halogen atoms and alkyl, alkoxy, thioalkyl, trifluoromethyl and phenyl groups.
- the octasaccharides according to the invention are synthetic oligosaccharides, that is to say they are compounds obtained by total synthesis from intermediate synthons, as will be described in detail in the following. In this respect, they differ from oligosaccharides obtained by depolymerization or isolation from complex mixtures of polysaccharides, of heparin or heparin type of low molecular weight.
- the compounds according to the invention have a well-defined structure resulting from their chemical synthesis and are in the form of pure octasaccharides, that is to say free of other oligosaccharide species.
- the invention encompasses compounds of formula (I) in acid form or in the form of any of their pharmaceutically acceptable salts.
- the -COO " and -SO 3 " functions are respectively in the form of -COOH and -SO 3 H.
- pharmaceutically acceptable salt means compounds of the invention, a compound in which one or more of the functions - COO " or / and -SO 3 " are ionically bonded to a pharmaceutically acceptable cation.
- the preferred salts according to the invention are those whose cation is chosen from alkali metal cations, in particular the Na + cation.
- the compounds of formula (I) according to the invention also include those in which one or more hydrogen or carbon atoms have been replaced by their radioactive isotope, for example tritium or C 14 carbon.
- radioactive isotope for example tritium or C 14 carbon.
- the disaccharide of formula (II) is bonded to the disaccharide unit represented in formula (I) by the oxygen atom located in position 1 of its glucosamine unit,
- glucosamine unit is understood to mean the monosaccharide unit of the following formula:
- the other type of saccharide unit present in the compounds according to the invention is a uronic acid, more specifically an iduronic acid, corresponding to the following formula:
- a uronic acid more specifically an iduronic acid
- the compounds of formula (I) according to the invention which are octasaccharides, can also be represented according to the formula (I ') as follows, in which the iduronic units and the glucosamine units follow one another and in which Ri, R 2, R3, Rs, R 7 and R 9 are as defined previously:
- alkyl group comprises from 5 to 16 carbon atoms, advantageously from 5 to 12 carbon atoms (for example a -O-pentyl, -O-undecyl or 2-propyl-pentyl group; )
- alkyl group contains from 1 to 8 carbon atoms, advantageously from 3 to 6 carbon atoms (for example a -O-propyl or -O-pentyl group), and is substituted by 1 or 2 groups, identical or different, chosen from aryl and cycloalkyl groups (for example phenyl and cycloalkyl groups, such as cyclohexyl).
- R 3 represents either an alkyl group comprising from 2 to 6 carbon atoms (for example a propyl or pentyl group), a cycloalkyl group (for example a cyclopentyl group).
- alkyl group comprises from 5 to 16 carbon atoms, advantageously from 5 to 12 carbon atoms (for example a -O-pentyl, -O-undecyl or 2-propyl-pentyl group) ,
- alkyl group contains from 1 to 8 carbon atoms, advantageously from 3 to 6 carbon atoms (for example a -O-propyl or -O-pentyl group), and is substituted with 1 or 2 groups, identical or different, chosen from aryl and cycloalkyl groups (for example phenyl and cycloalkyl groups, such as cyclohexyl),
- R 3 represents either an alkyl group comprising from 2 to 6 carbon atoms (for example a propyl or pentyl group), or a cycloalkyl group (for example a cyclopentyl group), and
- At least one of the groups R 2 , R 5 , R 7 and R 9 represents a hydroxyl group.
- the compounds of the invention there may be mentioned the following octasaccharides:
- the process for preparing the compounds according to the invention uses di- or oligosaccharide base synthons prepared as previously reported in the literature. Reference is made in particular to patents or patent applications EP 0 300 099, EP 0 529 715, EP 0 621 282 and EP 0 649 854, as well as the publication of C. Van Boeckel and M. Petitou published in Angew. Chem. Int. Ed. Engl., 1993, 32, 1671-1690. These synthons are then coupled to each other so as to provide a fully protected equivalent of an octasaccharide according to the invention. This protected equivalent is then converted into a compound according to the invention. In the coupling reactions mentioned above, a "donor" di- or oligosaccharide, activated on its anomeric carbon, reacts with a "acceptor” di- or oligosaccharide having a free hydroxyl.
- the present invention therefore relates to a process for the preparation of the octasaccharides of formula (I) / (I '), characterized in that:
- the N-acyl groups are introduced (introduction of the R 3 -CO- groups).
- the synthesis of the completely protected equivalent of the desired octasaccharide (I) is carried out according to reactions well known to those skilled in the art, using the methods for the synthesis of oligosaccharides (for example GJ, Boons, Tetrahedron (1996), 52, 1095-1121 and patent applications WO 98/03554 and WO 99/36443), wherein a glycosidic link donor oligosaccharide is coupled with a glycosidic link acceptor oligosaccharide to lead to another oligosaccharide whose size is equal to the sum of the sizes of the two reactive species. This sequence is repeated until the compound of formula (I) is obtained, optionally in protected form.
- oligosaccharides for example GJ, Boons, Tetrahedron (1996), 52, 1095-1121 and patent applications WO 98/03554 and WO 99/36443
- the nature and the charge profile of the desired final compound determine the nature of the chemical entities used in the various steps of the synthesis, according to the rules well known to those skilled in the art.
- the compounds of the invention can naturally be prepared using various strategies known to those skilled in the art of oligosaccharide synthesis. The process described above is the preferred method of the invention.
- the compounds of formula (I) / (I ') can be prepared by other well known methods of the chemistry of sugars, described for example in “Monosaccharides, Their chemistry and their roles in natural products", PM Collins and RJ. Ferrier, J. Wiley & Sons (1995) and by GJ. Boons in Tetrahedron (1996), 52, 1095-1 121.
- the protective groups used in the process for the preparation of the compounds of formula (I) / (I ') are those which make it possible, on the one hand, to protect a reactive function such as a hydroxyl or an amine during a synthesis and, d on the other hand, to regenerate the intact reactive function at the end of synthesis.
- the protective groups commonly used in the chemistry of sugars as described for example in "Protective Groups in Organic Synthesis", Green et al., 3 rd Edition (John Wiley & Sons, Inc., New York).
- the protecting groups are chosen, for example, from acetyl, methyl, pentenyl, benzoyl, levulinyl, benzyl, substituted benzyl, azides, benzyl carbamate, tert-butyldimethylsilyl (tBDMS) or tert-butyldiphenylsilyl (tBDPS) groups.
- Activator groups may also be used; these are those conventionally used in sugar chemistry, for example according to GJ. Boons, Tetrahedron (1996), 52, 1095-121. These activating groups are chosen for example from imidates or thioglycosides.
- the process described above makes it possible to obtain the compounds of the invention in the form of salts, advantageously in the form of the sodium salt.
- the compounds of the invention in the form of salts can be contacted with a cation exchange resin in acid form.
- the compounds of the invention in the form of acids can then be neutralized with a base to obtain the desired salt.
- any mineral or organic base giving, with the compounds of formula (I) / (I') pharmaceutically acceptable salts may be used.
- the subject of the invention is also the compounds of formula (V) below, in which Alk represents an alkyl group, Ri is as defined previously in with the compounds of formula (I) / (I '), bet Pg, Pg' and Pg ", which are identical to or different from one another, represent protective groups:
- Such compounds are useful as synthesis intermediates for the compounds of formula (I) / (I ').
- the subject of the invention is the compounds (V) in which Alk represents a methyl group and Pg, Pg 'and Pg "respectively represent benzyl, tBDPS and acetyl groups, More particularly from these compounds of formula (V), the invention is directed to those wherein R 1 is selected from the following groups: -O-methyl, -O- (CH 2 ) 5 -phenyl, -O-CH 2 -CH (C 3 H 7 ) 2, -O- (CH 2 ) SC 6 H 11 and -O- (CH 2 ) 2 -CH (phenyl) 2 .
- Such compounds correspond to the disaccharides 58, 131, 132, 133 and 134 illustrated in the following synthetic schemes, which are useful for the synthesis of compounds 10, 11 and 14 to 19 according to the invention, such as will be detailed in the following.
- the subject of the invention is also the compounds of formula (VI) below, in which Alk represents an alkyl group and Pg, Pg 'and Pg ", which are identical or different from one another, represent protective groups:
- Such compounds are useful as synthesis intermediates for the compounds of formula (I) / (I).
- the subject of the invention is the compound (VI) in which Alk represents a methyl group and Pg, Pg 'and Pg "respectively represent benzyl, levulinyl and acetyl groups,
- Such a compound corresponds to the disaccharide 24 illustrated in the diagrams Synthesis which follows, which is useful for the synthesis of compounds 1 to 4 according to the invention, as will be detailed in the following.
- Rf Retardation factor (retention time measured on the TLC compared to the front of the migration solvent)
- reaction mixture is diluted with ethyl acetate, washed with water, dried (Na 2 SO 4 ), filtered and concentrated, then purified on silica gel (acetone-cyclohexane) to lead to 21 (15.8 g, 76%).
- reaction mixture After 10 min of magnetic stirring at 0 ° C., then 1 h 45 at room temperature, the reaction mixture is diluted with dichloromethane, then successively washed with a 10% aqueous solution of potassium hydrogen sulphate, with water, and then with organic phase is dried (Na 2 SO 4 ), filtered and concentrated.
- the resulting residue is dissolved in ⁇ - / -dimethylformamide (210 mL), and potassium hydrogen carbonate (17 g, 5 molar equivalents) as well as methyl iodide (21 mL, 10 molar equivalents). are added together.
- the reaction mixture is stirred at ambient temperature for 16 hours and then concentrated in vacuo.
- the residue is diluted with ethyl acetate and then washed with water, with a saturated aqueous solution of sodium thiosulfate, with a saturated aqueous sodium chloride solution, then dried (Na 2 SO 4 ), filtered and concentrated.
- the compound obtained is engaged in the next step without purification.
- a solution of tert-butyldimethylsilyl triflate in dichloromethane (1 M, 0.1 mole per mole of imidate) is added, under argon, at -15 ° C, to a solution of imidate 38 (2.61 g 2.92 mmol) and glycosyl acceptor 31 (4.78 g, 2.25 mmol) in dichloromethane (146 ml) in the presence of 4 ⁇ molecular sieve (1.99 g).
- imidate 38 is again added at intervals of between 15 and 30 min, until the maximum consumption of the acceptor 31 is reached.
- reaction mixture After filtration and partial concentration, the reaction mixture is purified on LH-20 exclusion column using a 1: 1 methanol / dichloromethane mixture as eluent, then after collecting the fractions containing the product and concentration in vacuo, the residue is purified on silica gel with dichloromethane / ethyl acetate / ethanol to provide compound 40 (185 mg, 69%).
- Triethylamine / sulfur trioxide complex (513 mg, 5 moles per hydroxyl function) is added to a solution in ⁇ /, ⁇ -dimethylformamide (6.3 ml, 90 L / mol) of compound 40 (178 mg, 70.8 ⁇ mol). .
- methanol is added at 0 ° C. and after 0.5 h of stirring at 0 ° C. and 0.5 h at room temperature, the reaction medium is purified. using an LH-20 column using a 9: 1 methanol / ⁇ /, ⁇ / -dimethylformamide mixture as eluent.
- the product-containing fractions are then concentrated under high vacuum to yield the desired compound 41 (241 mg, 87%).
- reaction mixture After filtration and partial concentration, the reaction mixture is purified on LH-20 exclusion column using a 1: 1 methanol / dichloromethane mixture as eluent, then after collecting the fractions containing the product and concentration in vacuo, the residue is purified on silica gel with toluene / acetone / ethyl acetate / ethanol to provide 46 (83 mg, 61%).
- reaction mixture After filtration and partial concentration, the reaction mixture is purified on LH-20 exclusion column using a 1: 1 methanol / dichloromethane mixture as eluent, then after collecting the fractions containing the product and concentration in vacuo, the residue is purified on silica gel with dichloromethane / ethyl acetate / ethanol to provide compound 47 (141 mg, 69%).
- Triethylamine / sulfur trioxide complex (225 mg, 5 moles per hydroxyl function) was added to a solution in ⁇ -dimethylformamide (2.8 ml, 90 L / mol) of compound 46 (81 mg, 31 ⁇ mol). . After 16 hours of magnetic stirring at 50 ° C. in the absence of light, methanol (0.2 ml) is added at 0 ° C. and after stirring for 35 minutes at room temperature.
- reaction mixture is purified using an LH-20 column using a 1: 1: 0.1 methanol / dichloromethane / ⁇ /, ⁇ / - dimethylformamide as the eluent. Fractions containing the product are then concentrated under high vacuum to yield the desired compound 48 (122 mg, 99%).
- Triethylamine / sulfur trioxide complex (385 mg, 5 moles per hydroxyl function) was added to a solution in ⁇ -dimethylformamide (4.7 ml, 90 L / mol) of compound 47 (138 mg, 53 ⁇ mol). .
- methanol (0.35 ml) is added at 0 ° C. and after stirring for 30 minutes at 0 ° C. and then for 1 hour at room temperature, The reaction medium is purified using an LH-20 column using a mixture of 1: 1: 0.1 methanol / dichloromethane / N, N-dimethylformamide as eluent. Fractions containing the product are then concentrated under high vacuum to yield the desired compound 49 (194 mg, 92%).
- Rf 0.37, silica gel, cyclohexane / ethyl acetate 1/3
- Rf 0.23, silica gel, cyclohexane / ethyl acetate 1/3
- Rf 0.42, silica gel, cyclohexane / ethyl acetate 2/1
- Rf 0.40, silica gel, cyclohexane / ethyl acetate 2/1.
- Rf 0.30, silica gel, cyclohexane / ethyl acetate 2/1
- Rf 0.34, silica gel, cyclohexane / ethyl acetate 2/1
- reaction mixture After stirring for 8 hours at room temperature, the reaction mixture is placed at -18 ° C. for 16 h and then again for 2.5 h at room temperature. The medium is then diluted with ethyl acetate and then neutralized with 1N HCl in cold (0-4 ° C.), washed with water, dried (Na 2 SO 4 ), filtered and concentrated. and purified on silica gel (ethyl acetate - cyclohexane 15/85) to yield 70 (3.83 g, 91%).
- Rf 0.26, silica gel, ethyl acetate / pyridine / acetic acid / water 28/16 / 3.8 / 9.
- a mixture of the glycosyl acceptor 65 (1.82 g, 1.00 mmol), imidate 27 (1.35 g, 1.50 mmol), and 4 ⁇ molecular sieve powder (1, 12 g) in dichloromethane (52 ml) is stirred under argon for 1 hour at 25 ° C.
- the reaction mixture is cooled to -20 ° C. and then a 1M solution of tert-butyldimethylsilyl triflate in dichloromethane (224 ⁇ l) is added. After 50 minutes, the reaction medium is neutralized by addition of sodium hydrogencarbonate solid. After filtration through Celite ®, the reaction mixture is diluted with dichloromethane (500 ml_).
- Compound 80 (820 mg, 0.257 mmol) is saponified according to the method used for the preparation of compound 73 to give octasaccharide 81 (593.8 mg) after flash chromatography on silica gel column (toluene / acetone 1/0 ⁇ 0/1).
- reaction mixture is deposited on a Sephadex ® LH20 (120 x 3 cm, dichloromethane / ethanol 1/1) followed by flash chromatography on silica gel column (methanol / water 95/5) to give compound 83 (62.7 mg).
- Rf 0.27, silica gel, ethyl acetate / pyridine / acetic acid / water 17/9 / 2.2 / 5.
- Rf 0.37, silica gel, ethyl acetate / pyridine / acetic acid / water 17/9 / 2.2 / 5.
- Rf 0.25, silica gel, ethyl acetate / pyridine / acetic acid / water 17/9 / 2.2 / 5.
- Triethylamine / sulfur trioxide complex (761 mg, 5 moles per hydroxyl function) is added to a solution in ⁇ -dimethylformamide (11 ml, 90 L / mol) of compound 96 (324 mg, 120 ⁇ mol). ). After 17 hours of magnetic stirring at 55 ° C. in the dark, methanol is added at 0 ° C. and after 0.5 h of stirring at 0 ° C.
- the reaction medium is diluted with methanol and then purified using an LH-20 column using a 1: 1 methanol / dichloromethane mixture as eluent.
- the fractions containing the product are then concentrated under high vacuum and, if necessary, reactivated under the same conditions.
- the compound obtained 97 is then directly engaged in the next step.
- Rf 0.5 (AcOEt-pyridine-AcOH-H 2 O 1 1/7 / 1.6 / 4).
- Triethylamine / sulfur trioxide complex (376 mg, 5 moles per hydroxyl function) is added to a solution in ⁇ -dimethylformamide (5.3 ml, 90 L / mol) of compound 101 (160 mg, 59 ⁇ mol). .
- methanol is added at 0 ° C. and after 0.5 h of stirring at 0 ° C. and then 0.5 h at room temperature, the reaction medium is diluted. by methanol and then purified using an LH-20 column using a 1: 1 ethanol / dichloromethane mixture as eluent. The fractions containing the product are then concentrated under high vacuum. The compound obtained is then directly engaged in the next step.
- Rf 0.24 (cyclohexane - acetone 7/3).
- Triethylamine / sulfur trioxide complex (267 mg, 5 moles hydroxyl function) to a solution in ⁇ /, ⁇ -dimethylformamide (4.4 ml, 90 L / mol) of compound 109 (144 mg, 49 ⁇ mol).
- methanol is added at 0 ° C. and after 0.5 h of stirring at 0 ° C. and 0.5 h at room temperature, the reaction medium is diluted. with methanol and then purified using an LH-20 column using a 1: 1 methanol / dichloromethane mixture as eluent. The fractions containing the product are then concentrated under high vacuum. The compound obtained is then directly engaged in the next step.
- Triethylamine / sulfur trioxide complex (317 mg, 5 moles per hydroxyl function) is added to a solution in ⁇ /, ⁇ -dimethylformamide (4.5 ml, 90 L / mol) of compound 114 (135 mg, 50 ⁇ mol). .
- methanol is added at 0 ° C. and after 0.5 h of stirring at 0 ° C. and 0.5 h at room temperature, the reaction medium is diluted. by methanol and then purified using an LH-20 column using a 1: 1 ethanol / dichloromethane mixture as eluent. The fractions containing the product are then concentrated under high vacuum. Compound 115 (168 mg, 86%) is then obtained.
- Compound 122 (0.844 g, 0.80 mmol) is treated according to a protocol similar to that described for the synthesis of 124. In case of non completion of the reaction, the same amount of reagent may optionally be added. After treatment, the compound 126 is directly engaged in the next step.
- Rf 0.41 (cyclohexane-acetone 3/2).
- the compound 123 obtained above is dissolved in dichloromethane (173 ml). At 0 ° C. and under argon, triethylamine (7.6 ml, 2.5 molar equivalents), 4-dimethylaminopyridine (1.3 g, 0.5 molar equivalents) and tert-butyldiphenylsilyl chloride (1.2 ml.sup.3) are added successively. 2 molar equivalents). After 5.5 h of magnetic stirring, the reaction medium is diluted with dichloromethane, washed with an aqueous solution of potassium hydrogen sulfate at 10%, with a saturated aqueous solution of sodium chloride, dried
- Rf 0.46 (cyclohexane-acetone 3/2).
- Rf 0.42 (cyclohexane-acetone 7/3).
- glycosyl donor 63 (0.63 g, 0.57 mmol) and the glycosyl acceptor 133 (1.03 g, 0.95 mmol) are treated according to a protocol similar to that described for the synthesis of 136 to provide the compound 137 (716 mg, 62 mg). %).
- Rf 0.20 (cyclohexane-acetone 3/1).
- glycosyl donor 63 (0.63 g, 0.57 mmol) and the glycosyl acceptor 134 (0.83 g, 0.72 mmol) are treated according to a protocol similar to that described for the synthesis of 136 to provide compound 138.
- Rf 0.34 (cyclohexane-acetone 7/3).
- Rf 0.21 (cyclohexane-ethyl acetate 3/2).
- Rf 0.38 (cyclohexane-ethyl acetate 3/2).
- Rf 0.32 (cyclohexane-acetone 7/3).
- glycosyl donor 151 (0.56 g, 0.36 mmol) and the glycosyl acceptor
- Rf 0.36 (cyclohexane-acetone 3/2).
- glycosyl donor 151 (0.51 g, 0.33 mmol) and the glycosyl acceptor
- Rf 0.25 (cyclohexane-acetone 7/3).
- R (CH 2 J 3 Ph 2 Preparation of 5-phenylpentyl (methyl 3,4-di-O-benzyl- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-azido-3-O-benzyl-2-deoxy- ⁇ -D) -glucopyranosyl) - (1 ⁇ 4) - (methyl 3-O-benzyl- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-azido-3-O-benzyl-2-deoxy- ⁇ -D- glucopyranosyl) - (1 ⁇ 4) - (methyl 3-O-benzyl- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-azido-3-O-benzyl-6-O-tert-butyldiphenylsilyl) -2-deoxy- ⁇ -D-glucopy
- Rf 0.20 (cyclohexane-acetone 7/3).
- Triethylamine / sulfur trioxide complex (775 mg, 5 moles per hydroxyl function) is added to a solution in ⁇ /, ⁇ -dimethylformamide (12.8 ml, 90 L / mol) of compound 155 (438 mg, 142 ⁇ mol). .
- methanol is added at 0 ° C. and after 0.5 h of stirring at 0 ° C. and then at ambient temperature for 1 h, the reaction medium is diluted. by methanol and then purified using an LH-20 column using a 9: 1 methanol / N, N-dimethylformamide mixture as eluent.
- the product-containing fractions are then concentrated under high vacuum to yield the desired compound 159 (571 mg, 96%).
- Compound 156 (178 mg, 0.054 mmol) is treated according to a protocol similar to that described for the synthesis of 159 to provide 160 (196 mg, 75%).
- the product-containing fractions are then partially concentrated and then the residue is purified using an LH-20 column using a 9: 1 methanol / N-dimethylformamide mixture as eluent.
- the product-containing fractions are then concentrated under high vacuum to afford 163 (295 mg, 74%).
- Compound 168 is treated according to a protocol similar to that described for the synthesis of 171 to provide compound 172 (47 mg, 74% (2 steps)).
- EXAMPLE 1 Sodium pentyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate H1 ⁇ 4H2-acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D-glucopyranosyl)
- Pentyl (sodium 2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2- (1-oxobutyl) amino-6-O-sodium sulfonato- ⁇ - D-glucopyranosyl) - (1 ⁇ 4H 2 -O-sodium sulfonato- ⁇ -L-idopyranosyluronate sodium) - (1 ⁇ 4) - (2-deoxy-2- (1-oxobutyl) amino-6-O-sodium sulfonato - ⁇ -D-glucopyranosyl) -
- N-dimethylformamide / water 2.9 ml
- diisopropylethylamine 33 ⁇ l, 17 equivalents
- molar in solution in N, N-dimethylformamide (100 ⁇ l), as well as N-hydroxysuccinimide butyrate (27.4 mg,
- reaction medium is deposited on top of a Sephadex ® G-25 eluted with 0.2M sodium chloride was concentrated fractions containing product and desalified using the same column eluted by water. The product-containing fractions are then concentrated under high vacuum to yield the desired compound 2 (26 mg, 89%).
- EXAMPLE 3 Pentyl (sodium 2-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2- (1-oxohexyl) amino-6-O-sodium sulfonato- ⁇ - D-glucopyranosyl) - (1 ⁇ 4H 2 -O-sodium sulfonato- ⁇ -L-idopyranosyluronate sodium) -
- reaction medium is then deposited on top of a Sephadex ® G-25 eluted with 0.2M sodium chloride was concentrated fractions containing product and desalified using the same column eluted with water. The product-containing fractions are then concentrated under high vacuum to yield the desired compound 3 (4 mg, 34%).
- EXAMPLE 4 Pentyl (sodium 2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2 - [(cyclopentylcarbonyl) amino] -2-deoxy-6-O-sodium sulfonato- ⁇ -D - glucopyranosyl) - (1 ⁇ 4H 2 -O-sodium sulfonato- ⁇ -L-idopyranosyluronate sodium) -
- the reaction medium is deposited on top of a Sephadex ® G-25 eluted with 0.2M sodium chloride was concentrated fractions containing product and desalted using the same column eluted by water. The fractions containing the product are then concentrated under high vacuum to yield the desired compound 4 (5.6 mg, 55%). In case of incomplete reaction, the product obtained can be re-engaged under the same conditions.
- EXAMPLE 6 sodium 5-phenylpentyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D) -glucopyranosyl) -
- EXAMPLE 7 sodium methyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D-glucopyranosyl) r (1 ⁇ 4) - (sodium 2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D- glucopyranosyl) 1?
- EXAMPLE 8 Sodium Methyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate H1 ⁇ 4H2-acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4) - (2) Sodium ⁇ -Sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4H 2 -acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4) - (2-O) sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-acetamido-2-deoxy- ⁇ -D-glucopyranosyl) - (1 ⁇ 4H 2 -O-s
- EXAMPLE 10 Sodium Methyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate H1 ⁇ 4H2-acetamido-2-deoxy- ⁇ -D-glucopyranosyl) - (1 ⁇ 4H2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate of sodium) - (1 ⁇ 4) - (2-acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4) - (2-O-sodium sulfonato- ⁇ -L) - sodium idopyranosyluronate) - (1 ⁇ 4H2-acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4H2-O-
- EXAMPLE 1 1 Sodium methyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-acetamido-2-deoxy- ⁇ -D-glucopyranosyl) - (1 ⁇ 4) - (Sodium 2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4) Sodium (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D-glucopyranosyl) - (1) ⁇
- EXAMPLE 12 Sodium methyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D-glucopyranosyl)
- EXAMPLE 13 Sodium methyl-2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate H1 ⁇ 4H2-acetamido-2-deoxy-6-O-sodium sulfonato- ⁇ -D-glucopyranosyl (1 ⁇ 4) - (sodium 2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-acetamido-2-deoxy- ⁇ -D-glucopyranosyl) - (1 ⁇ 4) Sodium (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-acetamido-2-deoxy-6-O-sodium sulfonate- ⁇ -D-glucopyranosyl) - (1 ⁇ 4) - (sodium
- EXAMPLE 14 sodium 5-phenylpentyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2- (1-oxobutyl) amino-6-O-sodium sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4H2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2- (1-oxobutyl) amino-6- O-sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4) - (sodium 2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2-)
- reaction medium is deposited on top of a Sephadex ® G-25 eluted with 0.2M sodium chloride was concentrated fractions containing product and desalted using the same column eluted by water. Fractions containing the product are then concentrated under high vacuum to yield the desired compound 14 (133 mg, 93%).
- EXAMPLE 15 sodium 2-propyl-pentyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2- (1-oxobutyl) amino-6-O-sodium sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4H 2 -O-sodium sulfonato- ⁇ -L-idopyranosyluronate) -
- EXAMPLE 16 3-Cyclohexyl-propyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate sodium) -d ⁇ 4) - (2-deoxy-2-acetamido-6-O-sodium sulfonate- ⁇ -D- sodium glucopyranosyl) - (1 ⁇ 4H2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4H2-deoxy-2-acetamido-6-O-sodium sulfonato- ⁇ -D-glucopyranosyl-d ⁇ 4) Sodium (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) -d ⁇ 4) - (2-deoxy-2-acetamido- ⁇ -D-glucopyranosyl) -d ⁇
- EXAMPLE 17 3-Cyclohexyl-propyl (sodium 2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2- (1-oxobutyl) amino-6-O-sodium sodium sulfonato- ⁇ -D-glucopyranosylH1 ⁇ 4) - (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2- (1-oxobutyl) amino-6- O-sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4) - (sodium 2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2- (1)
- EXAMPLE 18 Sodium 3,3-diphenylpropyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2- (1-oxobutyl) amino-6-O) -sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4H 2 -O-sodium sulfonato- ⁇ -L-idopyranosyluronate sodium) - (1 ⁇ 4) - (2-deoxy-2- (1-oxobutyl) amino) Sodium 6-O-sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4) - (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2-) (1-
- N-dimethylformamide / water 4.8 mL
- diisopropylethylamine 63 ⁇ L, 15 molar equivalents
- N-dimethylformamide (43 ⁇ l) in solution in N, N-dimethylformamide (43 ⁇ l), as well as N-hydroxysuccinimide butyrate (49 mg, 11 molar equivalents) in solution in ⁇ /, ⁇ -dimethylformamide (43 ⁇ l).
- Stirring is maintained at room temperature for 3 hours, then the same amount of reagent is added under the same conditions three times.
- reaction medium is deposited on top of a Sephadex ® G-25 eluted with 0.2M sodium chloride was concentrated fractions containing product and desalted using the same column eluted by water. Fractions containing the product are then concentrated under high vacuum to yield the desired compound 18 (6 mg, 98%).
- EXAMPLE 19 sodium 5-phenylpentyl (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) - (1 ⁇ 4) - (2-deoxy-2- (3-methyl-1-oxobutyl) amino-6 Sodium ⁇ -sodium sulfonato- ⁇ -D-glucopyranosyl) - (1 ⁇ 4) - (2-O-sodium sulfonato- ⁇ -L-idopyranosyluronate) -
- the in vitro angiogenesis model corresponds to a rearrangement of human venous endothelial cells on a biological matrix.
- the matrix is formed by dispensing into each well of a 96 well plate (Becton Dickinson 353872), 60 .mu.l of Matrigel ® diluted 1/3 (Growth Factor Reduced Matrigel ®: Becton Dickinson 356230) in collagen (Rat Tail collagen, type I: Becton Dickinson 354249).
- the biological matrix cures after 1 hour at 37 ° C.
- Human venous endothelial cells (HUVEC ref: C-12200 - Promocell) seeded on the biological matrix at 7800 cells / well in 120 ⁇ l of EBM ® medium (Endothelial Basal Medium, Lonza C3121) + 2% FCS (fetal calf serum - Lonza) + hEGF (Recombinant Human Epidermal Growth Factor - Lonza) 10 ⁇ g / ml.
- the cells are stimulated with FGF2 (R & D Systems / 234-FSE-50) 10 ng / ml or with the products of the invention for 18 hours at 37 ° C in the presence of 5% CO 2 . After 24 hours, the cells are observed under a microscope (objective X4) and the analysis of the length of the pseudo-tubules is performed using an image software (BIOCOM-software Visiolab 2000).
- the compounds of the invention have a specific activity of between 10 -6 M and 10 -12 M.
- Compounds Nos. 1 and 2 are active at 10-11 M.
- This model is an adaptation of the model described by Andrade et al.
- Animals (white mice BALB / c inbred J) are anesthetized with Xylazine mixture (Rompun ®, 10 mg / kg) / Ketamine (Imalgene ® 1000, 100 mg / kg) intraperitoneally. The back of the animal is shaved and disinfected with Hexomedine ® . A pocket of air is created subcutaneously on the back of the mouse by injecting 5 ml of sterile air. An incision of about 2 cm, on the upper back of the animal is performed to introduce a sterile cellulose implant (disc 1 cm in diameter, 2 mm thick, Cellspon ® ref 0501) impregnated with 50 ⁇ l of sterile solution containing the product to be tested. The incision is then sutured and cleaned with Hexomedine ® .
- mice can receive in the implant the product by an injection through the skin (50 ⁇ l / implant / day) under gas anesthesia (Isoflurane 5% (Aerrane ® , Baxter)) .
- gas anesthesia Isoflurane 5% (Aerrane ® , Baxter)
- mice Seven days after laying the sponge, the mice are sacrificed by a lethal dose of Pentobarbital Sodium (CEVA Animal Health) administered intraperitoneally. The skin is then cut, about 1 cm around the sponge avoiding the scar to clear the skin and the sponge. The sponge is then cut into several pieces and placed in a Ribolyser ® tube containing 1 ml of lysis buffer (CeII Death Detection ELISA, Roche). The tubes are shaken 4 consecutive times, for 20 seconds, force 4, with the cell grinder (FastPrep ® FP 120). The tubes are then centrifuged for 10 minutes at 2000 g at 20 ° C. and the supernatants are frozen at -20 ° C. while waiting for the determination of hemoglobin.
- CeII Death Detection ELISA Roche
- the tubes are again centrifuged after thawing and the hemoglobin concentration is measured with Drabkin's reagent (Sigma, volume to volume) by spectrophotometer reading at 405 nm against a standard range of bovine hemoglobin (Sigma ).
- the concentration of hemoglobin in each sample is expressed in mg / ml according to the polynomial regression performed from the range. The results are expressed in mean value ( ⁇ sem) for each group. Differences between the groups are tested with ANOVA followed by a Dunnett test on the square root of the values.
- the compounds of the invention have demonstrated a specific activity of between 5 and 45 ng / site.
- Compounds No. 1 and 2 are active at 45 ng / site
- Compound No. 7 is active at 15 ng / site.
- compound No. 7 By way of comparison with a compound analogous to compound No. 7 according to the invention, but in which all the -NH-acyl groups are replaced by -NH-SO 3 - groups, compound No. 7 according to In this test, the present invention has an activity that is 21% higher than that of the fully sulfated analogue, which shows the importance of the N-acyl groups in the compounds according to the invention.
- pharmacokinetics The pharmacokinetic profile of the compounds according to the invention is evaluated after subcutaneous administration, in OF1 or C57 / BL6 mice, at a concentration of 30 mg / kg. The systemic exposure of the compounds is evaluated after single administration in the animal previously anesthetized with pentobarbital. The blood is removed from the vena cava and transferred to plastic tubes containing lithium heparin. After centrifugation (2000 g for 10 minutes at 8 ° C), the concentration of the compounds in the plasma is quantified by LC / MS-MS.
- the tested compounds show an improved pharmacokinetic profile (in particular AUC and higher plasma concentration, longer half-life times) compared to completely sulphated analogous compounds (replacement of N-acyl groups by groups).
- NH-SO 3 - the pharmacokinetic parameters of compounds 1, 6 and 7 according to the invention are described in the following table, in comparison with a fully sulfated analog No. 175 of the following formula:
- AUC Area Under the Curve between 0
- the invention therefore relates to medicaments which comprise a compound of formula (I) / (I ') according to the invention, or a pharmaceutically acceptable salt thereof.
- ischemia cardiac ischemia, arterial ischemia of the lower limbs
- diseases associated with a narrowing or obstruction of the arteries or arteritis the treatment of angina pectoris.
- treatment of thromboangiitis obliterans treatment of atherosclerosis, treatment of inhibition of restenosis after angioplasty or endoarterectomy, treatment of scarring, treatment for muscle regeneration, treatment for survival of myoblasts , treatment of peripheral neuropathy, treatment of postoperative nerve damage, treatment of nerve disorders such as Parkinson's disease, Alzheimer's disease, prion disease and neuronal degeneration in alcoholics, treatment of dementia, the treatment for improving the survival of the pancrofan bioartificial sheaves in the diabetic patient, the treatment of the improvement of graft revascularization and graft survival, the treatment of retinal degeneration, the treatment of retinitis pigmentosa, the treatment of osteoarthritis, the treatment of the pre - eclampsia or treatment of vascular lesions and acute respiratory distress syndrome, treatment for cartilage repair, treatment for bone repair and protection, treatment for repair and protection of hair follicles and for the protection and the regulation of capillary growth.
- Ischemia is a decrease in the arterial circulation in an organ resulting in a decrease in the oxygen concentration in the injured tissues.
- angiogenesis is the process of generating new capillaries from pre-existing vessels.
- Arteriogenesis contributes to the development (increase in size and caliber) of collateral vessels around the ischemic or avascular zone.
- FGF2 and in particular FGF-2 have been most widely described (Post, MJ, Laham, R., Sellke, FW & Simons, M. Therapeutic angiogenesis in cardiology using protein formulations, Cardiovasc Res 49, 522-31, 2001).
- FGF2 and its receptors represent highly relevant targets for therapies aimed at inducing the processes of angiogenesis and arteriogenesis (Khurana, R. & Simons, M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc Med 13, 1 16-22, 2003).
- One of the applications of the compounds of the invention is post-ischemic treatment after occlusion at the cardiac or peripheral arteries.
- cardiac ischemia one of the most promising clinical trials is a clinical trial in which FGF-2 was sequestered in microspheres of alginate in the presence of heparin (Laham, RJ et al. Local perivascular delivery of basic fibroblast growth factor in undergoing coronary bypass surgery patients: results of a phase I randomized, double-blind, placebo-controlled trial, Circulation 100, 1865-71, 1999).
- These micro-spheres were implanted near the ischemic focus at the level of the myocardium. After 90 days, all FGF2-treated patients had no ischemic heart symptoms.
- FGF2-mimicking compounds may be a therapy of choice for treating the consequences of cardiac ischemia.
- the compounds described in the invention may find an application in the treatment of diseases associated with a narrowing of the coronary arteries and in particular in the treatment of angina pectoris.
- Buerger's disease or thromboangiitis obliterans affects distal vascular structures and is characterized by distal arteritis of the legs with pain and ulceration.
- induction of angiogenesis and vasculogenesis would be a therapy for this pathology.
- the compounds of the present invention represent a therapy of choice for thromboangiitis obliterans.
- Peripheral neuropathy is an axonal or demyelinating lesion of the motor and / or sensory peripheral nerve that causes desensitization of the distal limbs.
- One of the major secondary complications of diabetes is the chronic development of peripheral neuropathy.
- FGF2 induces axonal regeneration which could be a therapy of choice in the treatment of peripheral nerve injury and thus in neuropathy.
- Peripheral fibroblast growth factor isoforms promote axonal elongation and branching of adult sensory neurons in vitro, Klimaschewski L, Nindl W, Feurle J, Kavakebi P, Kostron H. Neuroscience, 2004, 126 (2): 347-53). Because of the FGF receptor agonist activity, the compounds of said invention would be a treatment of choice in peripheral neuropathy in healthy or diabetic patients.
- FGF2 is an activator of nerve cells during development. Recent results suggest that FGF2 would also be a pivotal factor in promoting neuronal regeneration in adults (Sapieha PS, Peltier M, Rendahl KG, WC Manning, Di Polo A., Fibroblast growth factor-2 gene delivery stimulates axon growth by adult retinal ganglion cells after acute optic nerve injury Mol CeII Neurosci 2003 Nov; 24 (3): 656-72.
- the compounds of said invention would be a therapy of choice in the repair of postoperative nervous damage, in the repair of nerve deficits such as Parkinson's disease, Alzheimer's disease, prion disease , neuronal degeneration in the alcoholic or in cases of dementia.
- vascular smooth muscle cells contribute to intimal hypertrophy of the arteries and thus play a prominent role in atherosclerosis and restenosis after angioplasty and endoarterectomy.
- An angiogenic factor, VEGF has been shown to significantly reduce intimal thickening by accelerating re-endothelialization (Van Belle, E., Maillard, L., Tio, FO & Isner, JM Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation Biochem Biophys Res Commun 235, 31 1-6, 1997).
- the compounds of the present invention possessing pro-angiogenic activity may be useful in the treatment of atherosclerosis and in the inhibition of restenosis after angioplasty or endoarterectomy.
- the vascular network is essential for tissue development and preservation. By promoting the delivery of nutrients, oxygen and cells, blood vessels help maintain the functional and structural integrity of tissues.
- angiogenesis and vasculogenesis help to preserve and infuse tissue after ischemia.
- Angiogenic growth factors such as VEGF and FGF2 thus promote revascularization for tissue regeneration.
- the compounds presented in the invention could represent a treatment of choice in the treatment for the regeneration of muscles.
- the processes of muscle regeneration on dystrophic or normal muscles depend on the supply of cytokines and angiogenic growth factors at the local level (Fibbi, G., D'Alessio, S., Pucci, M., Cerletti, M. & Dei Rosso, M. Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system, Biol Chem 383, 127-36, 2002). It has been proposed that the FGF system is a critical system for muscle regeneration, survival and proliferation of myoblasts (Neuhaus, P.
- FGF fibroblast growth factor
- Angiogenesis is an essential phenomenon during cutaneous healing.
- the newly formed vessels provide the oxygen and nutrients needed for tissue repair.
- scarring is a slow and difficult process with angiogenesis defects.
- FGFS are among the growth factors most involved in angiogenesis processes during the healing phase.
- Some FGFs are highly over-regulated in dermal cells after a skin injury. By their FGF receptor agonist activities, the compounds of said invention would be a therapy of choice for the treatment of wound healing in healthy or diabetic patients.
- the compounds of said invention represent a therapy of choice in improving the survival of the bioartificial pancreas graft in the diabetic patient and more generally in the improvement of graft revascularization. and therefore in the survival of grafts.
- Retinitis pigmentosa is a pathology involving progressive degeneration of the retina characterized by degeneration of photoreceptors and obliteration of the retinal vessels.
- Lahdenranta et al. (An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration, Proc Natl Acad Sci USA 98, 10368-73, 2001) have proposed that angiogenic growth factors regulate neural coordination and associated retinal vascularization by functioning. simultaneously as photoreceptor survival factors and as regulator of endothelial cells.
- Pre-eclampsia is a pathology of the placenta associated with a lack of vascularization (Sherer, D. M. & Abulafia, O. Angiogenesis during implantation, and placental and early embryonic development, Placenta 22, 1-13, 2001). These defects of vascularization would be due to a defect of angiogenesis and would cause disturbances in the placenta which could lead to the death of the fetus.
- the compounds of the invention could be a treatment of choice to overcome a lack of angiogenesis in pre-eclamptic placentas.
- VEGF vascular endothelial growth factor
- FGF2 growth factors
- the intrinsic signaling pathway is activated by mitochondria in response to stress such as DNA deprivation or damage
- the extrinsic signaling pathway is induced by proapoptotic factor binding such as TNF- ⁇ or Fas.
- VEGF and FGF2 are two cell survival factors Endothelial (RoIe of Raf in Vascular Protection from Distinct Apoptotic Stimuli: A Alavi, JD Hood, R.
- Acute Respiratory Distress Syndrome is characterized by cardiovascular and neuropsychiatric problems.
- cardiovascular problems patients have significant vascular lesions and in particular an induction of apoptosis of endothelial cells high. Recently, Harnacher & al.
- bronchoalveolar lavage fluids from ARDS patients exhibited proapoptotic activity against microvascular lung endothelial cells (Tumor necrosis factor-alpha and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar washes of patients with acute respiratory distress syndrome Am J Respir Crit Care Med 2002 Sep 1; 166 (5): 651-6: Harnacher J, Lucas R, Lijnen HR, Buschke S, Dunant Y, Wendel A, Grau GE, Suter PM, Ricou B. ).
- the products of the invention could present a treatment of choice in the vascular improvement of patients with vascular lesions and in particular patients with ARDS.
- FGF7 or KGF
- FGF18 Is Highly Expressed in Hair Follicles and Capable of Inducing Anagen from Telogen Hair Follicles Stage: Mitsuko Kawano, Akiko Komi-Kuramochi, Masahiro Asada, Masashi Suzuki, Junko Oki, Ju Jiang and Toru Imamura).
- the compounds of said invention could present a treatment of choice for the repair and protection of hair follicles and in the protection and regulation of hair growth.
- the present invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention.
- These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt of said compound, as well as at least one pharmaceutically acceptable excipient.
- Said excipients are chosen according to the pharmaceutical form and the mode desired administration, among the usual excipients which are known to those skilled in the art.
- compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration the active ingredient of formula (I) ) above or its salt may be administered in unit dosage form, in admixture with conventional pharmaceutical excipients, to animals and humans for the prevention or treatment of the above disorders or diseases.
- Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, oral, intratracheal, intraocular, intranasal forms of administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants.
- oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions
- sublingual, oral, intratracheal intraocular, intranasal forms of administration by inhalation
- topical, transdermal, subcutaneous, intramuscular or intravenous administration forms rectal administration forms and implants.
- the compounds according to the invention can be used in creams, gels, ointments or lotions.
- Injectable administration forms are particularly advantageous, comprising conventionally the active compound dissolved in water for injection, in the presence of sodium chloride.
- the unit dose of active compound must be adapted to the desired therapeutic effect; it may be for example between 0.1 and 100 mg of active ingredient.
- the present invention also relates to a method of treatment of the pathologies indicated above which comprises the administration to a patient of an effective dose of a compound according to the invention or a pharmaceutically acceptable salt thereof acceptable.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012524265A JP5671536B2 (ja) | 2009-08-14 | 2010-08-12 | Fgf受容体活性化n−アシル8糖類、これの調製、およびこれの治療的使用 |
CA2771056A CA2771056C (fr) | 2009-08-14 | 2010-08-12 | Octasaccharides n-acyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique |
AU2010283614A AU2010283614B2 (en) | 2009-08-14 | 2010-08-12 | FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof |
EP10761049A EP2464667A2 (fr) | 2009-08-14 | 2010-08-12 | OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE |
NZ598174A NZ598174A (en) | 2009-08-14 | 2010-08-12 | Fgf receptor-activating n-acyl octasaccharides, preparation thereof, and therapeutic use thereof |
CN201080046585.0A CN102574931B (zh) | 2009-08-14 | 2010-08-12 | 激活fgf受体的n-酰基八糖、其制备方法、及其用途 |
EA201270277A EA020485B1 (ru) | 2009-08-14 | 2010-08-12 | N-ацилированные октасахариды, активирующие рецепторы fgf, их получение и применение в терапии |
KR1020127006510A KR101718567B1 (ko) | 2009-08-14 | 2010-08-12 | Fgf 수용체-활성화 n-아실 옥타사카라이드, 그의 제조법, 및 그의 치료 용도 |
BR112012007883A BR112012007883A2 (pt) | 2009-08-14 | 2010-08-12 | octa-sacarídeos n-acilas ativadores dos receptores dos fgfs, o respectivo preparo e a respectiva aplicação em terapêutica |
SG2012010203A SG178405A1 (en) | 2009-08-14 | 2010-08-12 | Fgf receptor-activating n-acyl octasaccharides, preparation thereof, and therapeutic use thereof |
MX2012001947A MX2012001947A (es) | 2009-08-14 | 2010-08-12 | Octasacaridos n-acilos activadores de los receptores de fgf, su preparacion y su uso en terapeutica. |
TNP2012000052A TN2012000052A1 (fr) | 2009-08-14 | 2012-02-03 | OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
US13/369,675 US9012413B2 (en) | 2009-08-14 | 2012-02-09 | FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof |
IL218068A IL218068A (en) | 2009-08-14 | 2012-02-12 | N-noble-octasaccharides that effect the fgf receptor, their preparation and medical use |
ZA2012/01028A ZA201201028B (en) | 2009-08-14 | 2012-02-13 | Fgf receptor-activating n-acyl octasaccharides,preparation thereof,and therapeutic use thereof |
MA34673A MA33573B1 (fr) | 2009-08-14 | 2012-03-08 | Octasaccharides n-acyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR09/03968 | 2009-08-14 | ||
FR0903968A FR2949114B1 (fr) | 2009-08-14 | 2009-08-14 | OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/369,675 Continuation US9012413B2 (en) | 2009-08-14 | 2012-02-09 | FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011018588A2 true WO2011018588A2 (fr) | 2011-02-17 |
WO2011018588A3 WO2011018588A3 (fr) | 2011-07-07 |
Family
ID=42035764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2010/051703 WO2011018588A2 (fr) | 2009-08-14 | 2010-08-12 | OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE |
Country Status (27)
Country | Link |
---|---|
US (1) | US9012413B2 (fr) |
EP (1) | EP2464667A2 (fr) |
JP (1) | JP5671536B2 (fr) |
KR (1) | KR101718567B1 (fr) |
CN (1) | CN102574931B (fr) |
AR (1) | AR078094A1 (fr) |
AU (1) | AU2010283614B2 (fr) |
BR (1) | BR112012007883A2 (fr) |
CA (1) | CA2771056C (fr) |
CL (1) | CL2012000393A1 (fr) |
CO (1) | CO6612193A2 (fr) |
DO (1) | DOP2012000037A (fr) |
EA (1) | EA020485B1 (fr) |
EC (1) | ECSP12011671A (fr) |
FR (1) | FR2949114B1 (fr) |
IL (1) | IL218068A (fr) |
MA (1) | MA33573B1 (fr) |
MX (1) | MX2012001947A (fr) |
NI (1) | NI201200026A (fr) |
NZ (1) | NZ598174A (fr) |
PE (1) | PE20120915A1 (fr) |
SG (2) | SG10201404221RA (fr) |
TN (1) | TN2012000052A1 (fr) |
TW (1) | TWI572615B (fr) |
UY (1) | UY32843A (fr) |
WO (1) | WO2011018588A2 (fr) |
ZA (1) | ZA201201028B (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013501838A (ja) * | 2009-08-14 | 2013-01-17 | サノフイ | Fgf受容体活性化n−硫酸塩オリゴ糖、該オリゴ糖の調製および該オリゴ糖の治療用途 |
EP2683746A1 (fr) * | 2011-03-10 | 2014-01-15 | Callaghan Innovation Research Limited | Composés oligosaccharidiques |
JP2014503674A (ja) * | 2011-01-27 | 2014-02-13 | サノフイ | Fgf受容体活性化3−o−アルキルオリゴ糖類、これの調製およびこれの治療的使用 |
US9012413B2 (en) | 2009-08-14 | 2015-04-21 | Sanofi | FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104370980B (zh) * | 2014-10-17 | 2017-12-01 | 九芝堂股份有限公司 | 一种抑制内源性因子x酶活性的寡糖类化合物及其药物组合物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0300099A1 (fr) | 1987-07-20 | 1989-01-25 | Akzo N.V. | Pentasaccharides |
EP0529715A1 (fr) | 1991-08-23 | 1993-03-03 | Akzo Nobel N.V. | Dérivés sulfatés de glycosaminoglycanoides |
EP0621282A1 (fr) | 1993-04-22 | 1994-10-26 | Elf Sanofi | 3-Désoxy oligosaccharides, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent |
EP0649854A1 (fr) | 1993-09-01 | 1995-04-26 | Akzo Nobel N.V. | Bisconjugués comprenant deux saccharides et un groupe de liaison |
WO1998003554A1 (fr) | 1996-07-19 | 1998-01-29 | Sanofi | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant |
WO1999036443A1 (fr) | 1998-01-19 | 1999-07-22 | Sanofi-Synthelabo | Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant |
WO2006021653A2 (fr) | 2004-07-23 | 2006-03-02 | Sanofi-Aventis | Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant, leur utilisation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US481816A (en) * | 1892-08-30 | Coin-controlled mechanism | ||
EP0333243A3 (fr) * | 1988-03-10 | 1989-09-27 | Akzo N.V. | Antigène K5 sulfaté et ses fragments |
AU1902592A (en) * | 1991-04-17 | 1992-11-17 | Glycomed Incorporated | Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation |
FR2749849B1 (fr) * | 1996-06-14 | 1998-09-04 | Sanofi Sa | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant |
US6617316B1 (en) | 1999-10-22 | 2003-09-09 | Aventis Pharma | Oligosaccharides, their preparation and pharmaceutical compositions containing them |
FR2800074B1 (fr) * | 1999-10-22 | 2001-12-21 | Aventis Pharma Sa | Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant |
US7582737B2 (en) | 2004-07-20 | 2009-09-01 | Academia Sinica | Orthogonally protected disaccharide building blocks for synthesis of heparin oligosaccharides |
EP2404939A3 (fr) * | 2006-05-25 | 2012-03-21 | Momenta Pharmaceuticals, Inc. | Composition d'héparine à faible poids moléculaire et utilisations associées |
FR2949114B1 (fr) | 2009-08-14 | 2011-08-26 | Sanofi Aventis | OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
-
2009
- 2009-08-14 FR FR0903968A patent/FR2949114B1/fr not_active Expired - Fee Related
-
2010
- 2010-08-12 NZ NZ598174A patent/NZ598174A/en not_active IP Right Cessation
- 2010-08-12 EA EA201270277A patent/EA020485B1/ru not_active IP Right Cessation
- 2010-08-12 CN CN201080046585.0A patent/CN102574931B/zh not_active Expired - Fee Related
- 2010-08-12 BR BR112012007883A patent/BR112012007883A2/pt active Search and Examination
- 2010-08-12 SG SG10201404221RA patent/SG10201404221RA/en unknown
- 2010-08-12 EP EP10761049A patent/EP2464667A2/fr not_active Withdrawn
- 2010-08-12 SG SG2012010203A patent/SG178405A1/en unknown
- 2010-08-12 JP JP2012524265A patent/JP5671536B2/ja not_active Expired - Fee Related
- 2010-08-12 AU AU2010283614A patent/AU2010283614B2/en not_active Ceased
- 2010-08-12 KR KR1020127006510A patent/KR101718567B1/ko active IP Right Grant
- 2010-08-12 PE PE2012000205A patent/PE20120915A1/es not_active Application Discontinuation
- 2010-08-12 WO PCT/FR2010/051703 patent/WO2011018588A2/fr active Application Filing
- 2010-08-12 CA CA2771056A patent/CA2771056C/fr active Active
- 2010-08-12 MX MX2012001947A patent/MX2012001947A/es active IP Right Grant
- 2010-08-13 AR ARP100102985A patent/AR078094A1/es unknown
- 2010-08-13 UY UY0001032843A patent/UY32843A/es not_active Application Discontinuation
- 2010-08-13 TW TW099127180A patent/TWI572615B/zh not_active IP Right Cessation
-
2012
- 2012-02-03 TN TNP2012000052A patent/TN2012000052A1/fr unknown
- 2012-02-08 DO DO2012000037A patent/DOP2012000037A/es unknown
- 2012-02-09 US US13/369,675 patent/US9012413B2/en not_active Expired - Fee Related
- 2012-02-12 IL IL218068A patent/IL218068A/en not_active IP Right Cessation
- 2012-02-13 ZA ZA2012/01028A patent/ZA201201028B/en unknown
- 2012-02-13 CO CO12024409A patent/CO6612193A2/es not_active Application Discontinuation
- 2012-02-13 NI NI201200026A patent/NI201200026A/es unknown
- 2012-02-13 EC ECSP12011671 patent/ECSP12011671A/es unknown
- 2012-02-14 CL CL2012000393A patent/CL2012000393A1/es unknown
- 2012-03-08 MA MA34673A patent/MA33573B1/fr unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0300099A1 (fr) | 1987-07-20 | 1989-01-25 | Akzo N.V. | Pentasaccharides |
EP0529715A1 (fr) | 1991-08-23 | 1993-03-03 | Akzo Nobel N.V. | Dérivés sulfatés de glycosaminoglycanoides |
EP0621282A1 (fr) | 1993-04-22 | 1994-10-26 | Elf Sanofi | 3-Désoxy oligosaccharides, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent |
EP0649854A1 (fr) | 1993-09-01 | 1995-04-26 | Akzo Nobel N.V. | Bisconjugués comprenant deux saccharides et un groupe de liaison |
WO1998003554A1 (fr) | 1996-07-19 | 1998-01-29 | Sanofi | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant |
WO1999036443A1 (fr) | 1998-01-19 | 1999-07-22 | Sanofi-Synthelabo | Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant |
WO2006021653A2 (fr) | 2004-07-23 | 2006-03-02 | Sanofi-Aventis | Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant, leur utilisation |
Non-Patent Citations (36)
Title |
---|
A ALAVIJ.D. HOODR. FRAUSTOD. G. STUPACKD.A. CHERESH: "Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli", SCIENCE, vol. 301, no. 5629, 4 July 2003 (2003-07-04), pages 94 - 96 |
A. ORITA ET AL., CHEM. EUR. J., vol. 7, 2001, pages 3321 |
ANDRADE ET AL., MICROVASCULAR RESEARCH, vol. 54, 1997, pages 253 - 61 |
C. NOTI ET AL., CHEM. EUR. J., vol. 12, 2006, pages 8664 - 8686 |
C. TABEUR ET AL., BIOORG. & MED. CHEM., vol. 7, 1999, pages 2003 - 2012 |
C. TABEUR, BIOORG. MED. CHEM., vol. 7, 1999, pages 2003 - 2012 |
C. TABEUR, CARBOHYDR. RES., vol. 281, 1996, pages 253 - 276 |
C. VAN BOECKELM. PETITOU, ANGEW. CHEM. INT. ED. ENGL., vol. 32, 1993, pages 1671 - 1690 |
C.A.A. VAN BOECKEL, J CARBOHYDR. CHEM., vol. 4, 1985, pages 293 - 321 |
CARBOHYDRATE RESEARCH, vol. 167, 1987, pages 67 - 75 |
CUEVAS PBURGOS JBAIRD A: "Basic fibroblast growth factor (FGF) promotes cartilage repair in vivo", BIOCHEM BIOPHYS RES COMMUN, vol. 156, no. 2, 31 October 1988 (1988-10-31), pages 611 - 8 |
FAKTOROVICH, E. G.STEINBERG, R. H.YASUMURA, D.MATTHES, M. T.LAVAIL, M. M.: "Basic fibroblast growth factor and local injury protect photoreceptors from light damage in the rat", J NEUROSCI, vol. 12, 1992, pages 3554 - 67 |
FIBBI, G.D'ALESSIO, S.PUCCI, M.CERLETTI, M.DEL ROSSO, M.: "Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system", BIOL CHEM, vol. 383, 2002, pages 127 - 36 |
G.J. BOONS, TETRAHEDRON, vol. 52, 1996, pages 1095 - 1121 |
GREEN ET AL.: "Protective Groups in Organic Synthesis", JOHN WILEY & SONS, INC. |
H. PAULSEN: "Advances in selective chemical syntheses of complex oligosaccharides", ANGEW. CHEM. INT. ED. ENGL., vol. 21, 1982, pages 155 - 173 |
HAMACHER JLUCAS RLIJNEN HRBUSCHKE SDUNANT YWENDEL AGRAU GESUTER PMRICOU B: "Tumor necrosis factor-alpha and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar lavages of patients with acute respiratory distress syndrome", AM J RESPIR CRIT CARE MED., vol. 166, no. 5, 1 September 2002 (2002-09-01), pages 651 - 6 |
HENDEL, R. C. ET AL.: "Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect", CIRCULATION, vol. 101, 2000, pages 118 - 21 |
KATO YGOSPODAROWICZ D: "Sulfated proteoglycan synthesis by confluent cultures of rabbit costal chondrocytes grown in the presence of fibroblast growth factor", J CELL BIOL., vol. 100, no. 2, February 1985 (1985-02-01), pages 477 - 85 |
KAWAGUCHI HNAKAMURA KTABATA YIKADA YAOYAMAANZAI JNAKAMURA THIYAMA YTAMURA M., J CLIN ENDOCRINOL METAB., vol. 86, no. 2, February 2001 (2001-02-01), pages 875 - 880 |
KHURANA, R.SIMONS, M.: "Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease", TRENDS CARDIOVASC MED, vol. 13, 2003, pages 116 - 22 |
KLIMASCHEWSKI LNINDL WFEURLE JKAVAKEBI PKOSTRON H, NEUROSCIENCE, vol. 126, no. 2, 2004, pages 347 - 53 |
LAHAM, R. J. ET AL.: "Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study", J AM COLL CARDIOL, vol. 36, 2000, pages 2132 - 9 |
LAHAM, R. J. ET AL.: "Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase 1 randomized, double-blind, placebo-controlled trial", CIRCULATION, vol. 100, 1999, pages 1865 - 71 |
LAHDENRANTA ET AL.: "An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration", PROC NATL ACAD SCI USA, vol. 98, 2001, pages 10368 - 73 |
LAZAROUS, D. F. ET AL.: "Basic fibroblast growth factor in patients with intermittent claudication: results of a phase 1 trial", J AM COLL CARDIOL, vol. 36, 2000, pages 1239 - 44 |
NEUHAUS, P. ET AL.: "Reduced mobility of fibroblast growth factor (FGF)-deficient myoblasts might contribute to dystrophic changes in the musculature of FGF2/FGF6/mdx triple-mutant mice", MOL CELL BIOL, vol. 23, 2003, pages 6037 - 48 |
P.M. COLLINSR.J. FERRIER: "Monosaccharides, Their chemistry and their roles in natural products", 1995, J. WILEY & SONS |
POST, M. J.LAHAM, R.SELLKE, F. W.SIMONS, M.: "Therapeutic angiogenesis in cardiology using protein formulations", CARDIOVASC RES, vol. 49, 2001, pages 522 - 31 |
SAKURAITOMONORISATAKEAKIRASUMISHOICHIROINOUEKAZUTOMONAGATANATSUKI: "The Efficient Prevascularization Induced by Fibroblast Growth Factor 2 With a Collagen-Coated Device Improves the Cell Survival of a Bioartificial Pancreas", PANCREAS, vol. 28, no. 3, April 2004 (2004-04-01), pages E70 - E79 |
SAPIEHA PSPELTIER MRENDAHL KGMANNING WCDI POLO A.: "Fibroblast growth factor-2 gene delivery stimulates axon growth by adult retinal ganglion cells after acute optic nerve injury", MOL CELL NEUROSCI., vol. 24, no. 3, November 2003 (2003-11-01), pages 656 - 72 |
SHERER, D. M.ABULAFIA, O.: "Angiogenesis during implantation, and placental and early embryonic development", PLACENTA, vol. 22, 2001, pages 1 - 13 |
SIMONS, M. ET AL.: "Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial", CIRCULATION, vol. 105, 2002, pages 788 - 93 |
TAKAFUJI HSUZUKI TOKUBO YFUJIMURA KBESSHO K: "Regeneration of articular cartilage defects in the temporomandibular joint of rabbits by fibroblast growth factor-2: a pilot study", INT J ORAL MAXILLOFAC SURG., vol. 36, no. 10, October 2007 (2007-10-01), pages 934 - 7 |
UNGER, E. F. ET AL.: "Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris", AM J CARDIOL, vol. 85, 2000, pages 1414 - 9 |
VAN BELLE, E.MAILLARD, L.TIO, F. O.ISNER, J. M.: "Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimai formation", BIOCHEM BIOPHYS RES COMMUN, vol. 235, 1997, pages 311 - 6 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013501838A (ja) * | 2009-08-14 | 2013-01-17 | サノフイ | Fgf受容体活性化n−硫酸塩オリゴ糖、該オリゴ糖の調製および該オリゴ糖の治療用途 |
US9012413B2 (en) | 2009-08-14 | 2015-04-21 | Sanofi | FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof |
JP2014503674A (ja) * | 2011-01-27 | 2014-02-13 | サノフイ | Fgf受容体活性化3−o−アルキルオリゴ糖類、これの調製およびこれの治療的使用 |
EP2683746A1 (fr) * | 2011-03-10 | 2014-01-15 | Callaghan Innovation Research Limited | Composés oligosaccharidiques |
JP2014508837A (ja) * | 2011-03-10 | 2014-04-10 | キャラハン イノベーション リサーチ リミテッド | オリゴ糖化合物 |
EP2683746A4 (fr) * | 2011-03-10 | 2014-09-03 | Callaghan Innovation Res Ltd | Composés oligosaccharidiques |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1322673A1 (fr) | Polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine | |
WO2011018588A2 (fr) | OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE | |
CA2577258C (fr) | Hexadecasaccharides biotinyles, leur preparation et leur utilisation comme anticoagulants et antithrombotique de l'heparine | |
CA2771055C (fr) | Oligosaccharides n-sulfates activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique | |
KR20030001394A (ko) | 올리고사카라이드-함유 약학 조성물 및 이의 제조방법 | |
FR2970969A1 (fr) | Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080046585.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10761049 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 289/KOLNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000205-2012 Country of ref document: PE Ref document number: CR2012-000071 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 218068 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2771056 Country of ref document: CA Ref document number: 2012524265 Country of ref document: JP Ref document number: 12024409 Country of ref document: CO Ref document number: 12012500302 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 0150312 Country of ref document: KE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012000393 Country of ref document: CL Ref document number: 1201000585 Country of ref document: TH Ref document number: MX/A/2012/001947 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010283614 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010761049 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010283614 Country of ref document: AU Date of ref document: 20100812 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20127006510 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201202973 Country of ref document: UA Ref document number: 201270277 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012007883 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012007883 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120405 |